基于熵权法的我国制药业创新能力的综合评价  

Analysis in Innovation Ability of China Pharmaceuticals Based on Entropy Weight

作　　者：褚淑贞[1] 唐卉[1] 

机构地区：[1]中国药科大学医药产业发展研究中心,江苏南京211198

出　　处：《中国药物评价》2013年第5期295-297,301,共4页Chinese Journal of Drug Evaluation

摘　　要：目的:基于我国制药业的基本情况,分析及预测我国制药业创新能力,并提出改进建议。方法:通过分析目前我国制药业创新现状,构建基于熵权法的指标体系,计算出2001年以来制药业创新能力评价综合得分序列。结果与结论:我国制药业的创新能力呈现持续改善趋势,企业办科研机构对创新能力影响较大,并提出提升制药业创新能力的建议。Objective： To analyze and predict the innovation ability of pharmacy of our country based on the situation of China phar- maceutical industry. Methods： Construct an assessment indicator system determined by entropy weight through the analysis of China pharmaceutical innovation ability, then calculate composite value sequence of innovation ability since 2001. Results and Conclusion： Pharmaceutical innovation ability has been continuous improved in China, of which the enterprise scientific research institutions count mostly. Meanwhile, some pharmacy innovation promotion suggestions are proposed.

关 键 词：制药业 创新能力 熵权法 时间序列 

分 类 号：F426.72[经济管理—产业经济] F273.1F224